NCT06961383: An ongoing trial by NeuroGenesis Ltd.
This trial is ongoing. It must report results 2 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06961383 |
|---|---|
| Title | A Double Blind, Randomized, Placebo Controlled Phase 2b Study to Evaluate the Safety and Clinical Efficacy of Treatment With the Autologous Cell Therapy Product, NG01, in Patients With Secondary Progressive Multiple Sclerosis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 1, 2025 |
| Completion date | Oct. 1, 2027 |
| Required reporting date | Sept. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |